Evolus investors frown as FDA declines to approve Botox rival

(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.


Source: Reuters Medical News

U.S. state lawsuits against Purdue Pharma over opioid epidemic mount

NEW YORK (Reuters) – Litigation against OxyContin maker Purdue Pharma LP is intensifying as six more U.S. states on Tuesday announced lawsuits, accusing the company of fueling a national opioid epidemic by deceptively marketing its prescription painkillers to generate billions of dollars in sales.


Source: Reuters Medical News

Nestle to cut more sugar and salt in its products

VEVEY, Switzerland (Reuters) – Nestle will make further cuts to the amount of sugar, salt and saturated fats in its products as it tries to improve the image of packaged foods in the eyes of health-conscious consumers, the Swiss group said on Tuesday. Nestle and its rivals are under pressure from a shift in consumer preferences toward healthier food and away from processed products such as instant noodles and frozen pizza.


Source: Reuters Medical News